← Back to headlines
Moderna Stock Jumps on FDA Flu Vaccine Review
Moderna's stock has risen above its 20-day moving average following the FDA's review of its flu vaccine, prompting questions about its investment potential.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
